A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer
Conclusions An MTD for the combination was not established. Cabozantinib and gemcitabine appear impractical for further development due to DLT at low doses and continuing toxicities with ongoing therapy. Acknowledging the small sample size, responses were seen suggesting further investigation of c-Met inhibition in PDAC may be warranted.
ConclusionsThe addition of tarextumab to nab ‐paclitaxel and gemcitabine did not improve OS, PFS, or ORR in first‐line metastatic PDAC, and PFS was specifically statistically worse in the tarextumab‐treated patients.Clinical trial registry noNCT01647828.
ConclusionsThe MTD/RPTD of GD is gemcitabine 1000 mg/m2 weekly for 3 of 4 weeks and dasatinib 50 mg PO BID. The clinical activity of GD seen in this study was modest, and does not support its further investigation in pancreatic cancer.
This study investigates trends in age distribution of patients enrolled in clinical trials for advanced pancreatic cancer over time, and examines outcomes and toxicity in older patient subgroups from two studies conducted by Eastern Cooperative Oncology Group and American College of Radiology Imaging Network (ECOG-ACRIN) in this disease.Materials and Methods16,042 patients from 38 phase III clinical trials for locally advanced or metastatic pancreatic adenocarcinoma published between 1997 and 2016 were identified and included in this analysis. Outcomes and toxicity by age were examined in two of the trials, ECOG-ACRIN tria...
Conclusion: Biweekly cisplatin, fixed-dose-rate gemcitabine, and infusional 5-FU demonstrated a high response rate and were well tolerated, encouraging further investigation of this regimen in metastatic pancreatic and biliary cancers.
CONCLUSIONSThe RP2D of veliparib was 80 mg by mouth twice daily on days 1 to 12 in combination with cisplatin and gemcitabine; the DLT was myelosuppression. Substantial antitumor activity was seen in BRCA+ PDAC. A randomized phase 2 trial is currently evaluating cisplatin and gemcitabine with and without veliparib for BRCA+ PDAC (NCT01585805). Cancer 2018. © 2018 American Cancer Society.
Conclusion.Acceptable safety and encouraging signals of activity in patients with metastatic pancreatic cancer receiving necuparanib, nab‐paclitaxel, and gemcitabine were demonstrated.
CONCLUSION: Acceptable safety and encouraging signals of activity in patients with metastatic pancreatic cancer receiving necuparanib, nab-paclitaxel, and gemcitabine were demonstrated. PMID: 29158367 [PubMed - as supplied by publisher]
SummaryPancreatic adenocarcinoma remains a major therapeutic challenge, as the poor (
CONCLUSIONSADI‐PEG 20 was well tolerated in combination with gemcitabine and nab‐paclitaxel. Activity was observed in previously treated and untreated patients with advanced pancreatic cancer and in patients with ASS1‐deficient and ‐proficient tumors. Cancer 2017. © 2017 American Cancer Society.
A previously healthy 54-year old man was diagnosed with metastatic pancreatic ductal adenocarcinoma (PDAC) in February 2015; the primary tumor was localized in the tail of the pancreas. Histological confirmation of disease was based on a liver biopsy that showed a poorly differentiated adenocarcinoma. The patient had no family history of PDAC; however, two of his paternal aunts died of breast cancer. The patient started chemotherapy with a FOLFIRINOX regimen in March 2015 , that was de-escalated to mFOLFOX-6 and finally 5-FU/FA due to toxicity (thrombocytopenia, peripheral neuropathy); maintenance 5-FU/FA was given unti...